CenterBook Partners LP Takes $2.36 Million Position in Repligen Corporation $RGEN
CenterBook Partners LP has acquired a new stake of 17,672 shares in Repligen Corporation (NASDAQ:RGEN) valued at approximately $2.36 million during the third quarter. This move is part of broader institutional investor activity, with other hedge funds also adjusting their positions in the biotechnology company. Insider trading news indicates a director recently sold 275 shares.
Repligen Corp. (RGEN) Rose as Industrial Destocking Decreased and Order Patterns Stabilized
Repligen Corporation (RGEN) shares rallied as industrial destocking eased and order patterns stabilized, according to Conestoga Capital Advisors' fourth-quarter 2025 investor letter. Despite trailing the Russell 2000 Growth Index for the quarter, the firm highlighted Repligen's strong market position and long-term growth prospects in biologics manufacturing. While 53 hedge funds held RGEN in Q3, Conestoga Capital Advisors noted that certain AI stocks might offer greater upside and less risk.
ABN Amro Investment Solutions Invests $151,000 in Repligen Corporation $RGEN
ABN Amro Investment Solutions recently acquired a new stake of 150,000 shares in Repligen (NASDAQ:RGEN) during Q3, valued at approximately $151,000. Institutional investors own a significant portion of Repligen's stock at 97.64%, while analysts currently hold a "Moderate Buy" consensus rating with a target price of $177.92. The biotechnology company, specializing in bioprocessing products, has seen various institutional investors adjust their positions, and its stock has traded within a one-year range of $102.96 to $175.77.
Repligen (NASDAQ:RGEN) Growth Sensitivity Mirrors Nasdaq Composite Moves
Repligen (NASDAQ:RGEN) is gaining attention in Nasdaq Composite discussions due to factors like institutional positioning, liquidity, and demand cycles in bioprocessing, influencing its valuation. The company specializes in bioprocessing consumables such as chromatography resins and filtration technologies. Its competitive edge lies in integrating specialized purification and filtration technologies into biologic workflows, renewed by capital rotation within biotech suppliers focusing on life sciences infrastructure.
Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Analysts
Repligen Corporation (NASDAQ:RGEN) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $177.92, suggesting potential upside from its current share price. Despite insider selling of 4,657 shares last quarter, institutional investors and hedge funds hold a significant 97.64% ownership. The company's strong financial metrics, including a debt-to-equity ratio of 0.26 and a current ratio of 8.36, further support its investment profile.
Liquidity Mapping Around (RGEN) Price Events
This article from Stock Traders Daily provides a liquidity mapping analysis for Repligen Corporation (NASDAQ: RGEN), highlighting a mid-channel oscillation pattern and a significant risk-reward setup. It details institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, showing weak near/mid-term sentiment but a strong long-term outlook. The report offers specific entry, target, and stop-loss levels derived from AI models.
TimesSquare Capital Management LLC Purchases 121,898 Shares of Repligen Corporation $RGEN
TimesSquare Capital Management LLC significantly increased its stake in Repligen Corporation (NASDAQ:RGEN) by 50.7% in Q3, acquiring 121,898 additional shares to own a total of 362,129 shares valued at $48.41 million. This increase reflects growing institutional confidence, although company insiders have sold approximately $706,877 worth of shares in the past 90 days. Repligen currently holds a "Moderate Buy" consensus rating from Wall Street analysts, with a consensus price target of $177.92.
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
Repligen Corporation announced it will report its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. The company will issue a press release before market open and host a conference call at 8:30 a.m. ET to discuss the financial results and business updates for the periods ended December 31, 2025. Both the conference call and a webcast will be accessible to the public, with an archived replay available afterward.
Repligen (RGEN) to Release Quarterly Earnings on Thursday
Repligen (NASDAQ:RGEN) is expected to release its Q4 2025 earnings before market open on Thursday, February 19th, with analysts anticipating earnings of $0.44 per share and revenue of $192.225 million. The company currently holds a "Moderate Buy" consensus rating from analysts, with insider selling activity noted over the past 90 days and significant institutional ownership. An earnings call is scheduled for February 24th to discuss the results.
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
Repligen Corporation (NASDAQ:RGEN) announced it will report its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. The company will issue a press release before market open and host a conference call at 8:30 a.m. ET to discuss the results and business updates. Interested parties can access the call via a toll-free number or a webcast on the Investor Relations section of Repligen’s website.
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
Repligen Corporation (NASDAQ:RGEN) announced it will report its fourth quarter and full-year 2025 financial results on Tuesday, February 24, 2026. The company will issue a press release before market open and host a conference call at 8:30 a.m. ET to discuss the results and business updates for the period ended December 31, 2025. The conference call and webcast details for investors were also provided.
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
Repligen Corporation announced it will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and business updates. Repligen is a global life sciences company specializing in bioprocessing technologies for biological drug manufacturing.
Azzad Asset Management Inc. ADV Has $1.09 Million Stock Holdings in Repligen Corporation $RGEN
Azzad Asset Management Inc. ADV reduced its stake in Repligen Corporation (NASDAQ:RGEN) by 60.7% in Q3, now holding 8,183 shares valued at approximately $1.09 million. Despite this, other institutions increased their positions, and Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $179.62. Company insiders have sold shares totaling $7.72 million in the last three months, while institutional investors own nearly 97.64% of the stock.
How Investors May Respond To Repligen (RGEN) Winning Backing For Its AI-Driven Bioprocessing Platform
Baron Health Care Fund recently added Repligen (RGEN) to its portfolio, citing the company's bioprocessing technology, AI for real-time drug production monitoring, and potential for growth from pharmaceutical reshoring. This endorsement reinforces Repligen's investment narrative as a key supplier to biopharma, though market sentiment suggests it may not be a major short-term driver. Investors are advised to consider various perspectives and risks, including valuation and execution, despite the fund's backing.
Why (RGEN) Price Action Is Critical for Tactical Trading
This article analyzes Repligen Corporation (NASDAQ: RGEN) stock, highlighting a weak near and mid-term sentiment despite a long-term positive outlook. It identifies a mid-channel oscillation pattern and an exceptional short setup with a 46.4:1 risk-reward ratio, targeting a 13.3% downside. Three distinct AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) are provided, along with multi-timeframe signal analysis.
WCM Investment Management LLC Trims Holdings in Repligen Corporation $RGEN
WCM Investment Management LLC significantly reduced its stake in Repligen Corporation (NASDAQ:RGEN) by 38.1% in the third quarter, now holding 67,999 shares valued at $8.44 million. Despite this, other institutional investors either increased their holdings or initiated new positions, and Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $179.62. Company insiders have been net sellers, disposing of shares worth approximately $7.72 million over the past 90 days.
Mirae Asset Global Investments Co. Ltd. Sells 10,260 Shares of Repligen Corporation $RGEN
Mirae Asset Global Investments Co. Ltd. reduced its stake in Repligen Corporation by 34.8%, selling 10,260 shares and holding 19,262 shares valued at $2.575 million. Company insiders have also been net sellers, with 49,657 shares sold over the last three months. Despite insider selling, analyst sentiment remains broadly positive, with a "Moderate Buy" consensus and an average price target of $179.62.
Brown Capital Management LLC Reduces Stock Holdings in Repligen Corporation $RGEN
Brown Capital Management LLC has reduced its stake in Repligen Corporation by 33.5% in the third quarter, now owning 668,858 shares valued at $89.4 million, which constitutes 3.7% of its portfolio. Despite insider selling activity, the consensus analyst rating for Repligen remains "Moderate Buy" with an average price target of $179.62. The biotechnology company, specializing in bioprocessing products, has seen mixed institutional investor activity with some increasing and others decreasing their positions.
Repligen Corporation (RGEN) Stock Analysis: Navigating a 27.80% Potential Upside in the Bioprocessing Sector
Repligen Corporation (RGEN) is a significant player in the bioprocessing sector, with a market capitalization of approximately $8.41 billion. Despite a recent minor stock dip, analysts are optimistic, projecting a 27.80% upside with an average target price of $190.89. The company showcases strong revenue growth of 21.90% and healthy free cash flow, reinvesting profits to enhance its innovative product portfolio and expand market reach.
Tangential Flow Filtration Market Booming with Rapid Growth
The Tangential Flow Filtration Market is projected to grow significantly from USD 2.13 billion in 2025 to USD 4.86 billion by 2032, at a CAGR of 12.5%. This growth is driven by rapid innovation and shifting regional dynamics, with key players like Sartorius AG and Repligen Corporation leading the market. The report segments the market by product type, technique, material, application, and end-user, offering strategic insights into investment hotspots and emerging trends.
Thrivent Financial for Lutherans Increases Stock Holdings in Repligen Corporation $RGEN
Thrivent Financial for Lutherans significantly increased its stake in Repligen Corporation (NASDAQ:RGEN) by 6.7% in the third quarter of 2025, now owning 458,820 shares valued at approximately $61.33 million. This comes despite recent insider selling by the company's director and COO. Analysts currently give Repligen a "Moderate Buy" rating with an average target price of $179.62, while the stock recently opened at $149.37.
Repligen Corp (RGEN) Stock Price Down 3.37% on Jan 29
Repligen Corp (RGEN) stock price dropped 3.37% on January 29, reaching an intraday low of $154.02 before settling at $154.66. Despite the dip, analysts predict an average one-year target price of $190.06, suggesting a 22.89% upside. GuruFocus also estimates a fair value of $188.20, indicating a 21.69% upside for the stock.
Kornitzer Capital Management Inc. KS Makes New $10.46 Million Investment in Repligen Corporation $RGEN
Kornitzer Capital Management Inc. KS has recently acquired a new stake in Repligen Corporation (NASDAQ:RGEN) valued at approximately $10.46 million, purchasing 78,280 shares in Q3. This investment represents about 0.14% of Repligen, a biotechnology company focused on bioprocessing applications. While institutional investors primarily hold Repligen stock, insiders have recently sold shares, and analysts currently rate the stock a "Moderate Buy" with an average target price of $179.62.
3 Reasons to Sell RGEN and 1 Stock to Buy Instead
Repligen Corp (RGEN) has seen a significant stock price increase, outperforming the S&P 500, but the author advises caution. Reasons to sell include slow organic growth indicating waning demand, shrinking adjusted operating margins, and declining return on invested capital. Instead, the article suggests looking at other market-beating stocks, particularly those identified by StockStory's High Quality list.
Understanding Momentum Shifts in (RGEN)
This article analyzes Repligen Corporation (RGEN) using AI models, highlighting a strong near-term sentiment with a neutral mid and long-term outlook. It identifies a significant risk-reward short setup and outlines three trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, complete with entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for RGEN.
UBS Tags Repligen (RGEN) as Bioprocessing Leader for 2026, Cites 20% Order Growth and Reshoring Tailwinds
UBS has identified Repligen (RGEN) as a leading bioprocessing company for 2026, driven by over 20% order growth and the increasing trend of reshoring manufacturing. The firm raised its price target for Repligen to $200, maintaining a Buy rating, and views the company as a key beneficiary as biopharma production shifts closer to primary markets. Repligen has also expanded its product portfolio with new high-performance chromatography resins designed for next-gen bioprocessing, particularly for gene therapy applications.
UBS Tags Repligen (RGEN) as Bioprocessing Leader for 2026, Cites 20% Order Growth and Reshoring Tailwinds
UBS has reaffirmed its Buy rating and raised Repligen's price target to $200, identifying the company as a bioprocessing leader for 2026. The firm anticipates over 20% order growth for Repligen, driven by diversified growth factors and the accelerating trend of reshoring in the biopharma sector. Additionally, Repligen recently launched new high-performance chromatography resins designed for next-generation bioprocessing, particularly for gene therapy viral vectors.
UBS Tags Repligen (RGEN) as Bioprocessing Leader for 2026, Cites 20% Order Growth and Reshoring Tailwinds
UBS has identified Repligen (RGEN) as a leading company in the bioprocessing sector for 2026, raising its price target to $200 and maintaining a Buy rating. The firm highlights Repligen's projected 20% order growth, expanding presence in Edge manufacturing, and the benefit from biopharma companies reshoring production. Additionally, Repligen recently launched new high-performance chromatography resins designed for next-gen bioprocessing, particularly for gene therapy viral vectors.
Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Analysts
MarketBeat reports that Repligen Corporation (NASDAQ:RGEN) has received a consensus "Moderate Buy" rating from fifteen analysts, with an average 1-year price target of $179.62. Recent analyst upgrades include Barclays and UBS raising their price targets to $200. The company recently surpassed quarterly earnings estimates, reporting $0.46 EPS against an expected $0.42, and posted revenues of $188.8 million, up 21.9% year-over-year.
Stephens Investment Management Group LLC Grows Stock Position in Repligen Corporation $RGEN
Stephens Investment Management Group LLC increased its stake in Repligen Corporation by 14.4% in the third quarter, acquiring an additional 75,509 shares, bringing their total holdings to 598,356 shares valued at approximately $79.98 million. Despite this institutional accumulation, corporate insiders have been net sellers, divesting 49,657 shares worth $7.72 million over the past 90 days. Repligen exceeded Q3 earnings estimates, and analysts maintain an average "Moderate Buy" rating with a target price of $179.62.
Repligen Corp (RGEN) Shares Up 3.89% on Jan 21
Shares of Repligen Corp (RGEN) rose 3.89% on January 21, closing at $169.68. This places the stock 7.03% below its 52-week high and 64.79% above its 52-week low. Analysts have an average target price of $190.06, suggesting a 12.01% upside, and an average brokerage recommendation of "Outperform."
Slow Capital Inc. Has $5.89 Million Holdings in Repligen Corporation $RGEN
Slow Capital Inc. increased its stake in Repligen Corporation (NASDAQ:RGEN) by 23.9% in the third quarter, bringing its total holdings to 44,076 shares valued at $5.89 million. Repligen reported strong Q3 earnings, beating revenue estimates by 21.9% year-over-year and setting positive FY2025 guidance. The company has an average analyst rating of "Moderate Buy" with a consensus price target of $179.62, though insider sales totaling 49,657 shares occurred recently.
UBS raises Repligen stock price target to $200 on bioprocessing recovery By Investing.com
UBS raised its stock price target for Repligen (NASDAQ:RGEN) to $200 from $190, maintaining a Buy rating due to expectations of a bioprocessing recovery and a return to mid-teens growth. The company is considered a "top pick" in the Life Science Tools & Services sector after exceeding sales expectations in 2025. This positive outlook is supported by Repligen's strong financial health and diverse growth drivers.
UBS raises Repligen stock price target to $200 on bioprocessing recovery
UBS has increased its price target for Repligen (NASDAQ:RGEN) to $200 from $190, maintaining a Buy rating. The firm views Repligen as well-positioned for recovery in the bioprocessing sector, citing its strong financial health and diverse growth drivers. This revised target follows Repligen's exceeded sales expectations and strong third-quarter earnings in 2025.
UBS raises Repligen stock price target to $200 on bioprocessing recovery
UBS has increased its price target for Repligen (NASDAQ:RGEN) to $200 from $190, maintaining a Buy rating, citing the company's strong position to benefit from a bioprocessing recovery and achieve mid-teens mid-term growth. Repligen's financial health is robust, with moderate debt and exceptional liquidity, making it a "top pick" for UBS in the Life Science Tools & Services sector. The company surpassed sales expectations in 2025, demonstrating diverse growth drivers, and recently reported strong Q3 2025 earnings, leading other analysts like Jefferies and Stifel to also adjust their outlooks positively.
Why Repligen (RGEN) Shares Are Sliding Today
Repligen (RGEN) shares fell 3.9% after the company presented at the JPMorgan Healthcare Conference and provided its 2025 sales guidance of $733 million, which investors seemingly found underwhelming. Despite this dip, the company previously reported strong Q2 2025 results with a 15% year-over-year revenue increase and raised its full-year guidance at that time. The stock is currently trading near its 52-week high, suggesting that investors may be looking for more robust growth in the bioprocessing sector.
Why Repligen (RGEN) Shares Are Sliding Today
Shares of biopharma manufacturing company Repligen Corporation fell 3.9% after the company presented its 2025 sales guidance of $733 million at the JPMorgan Healthcare Conference. Investors were reportedly underwhelmed by this sales forecast, expecting a more robust outlook. Despite the recent drop, the company's shares are trading near their 52-week high, and it had a strong Q2 2025 with a 15% revenue increase and raised full-year guidance.
Avoiding Lag: Real-Time Signals in (RGEN) Movement
This article analyzes Repligen Corporation (RGEN) using AI models, highlighting conflicting sentiment across different time horizons, suggesting choppy conditions. It provides institutional trading strategies including position, momentum breakout, and risk hedging, along with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for near-term, mid-term, and long-term outlooks.
Repligen nombra a Madaus como nuevo presidente de la junta, Hunt se jubilará
Repligen Corporation announced that Dr. Martin D. Madaus will become the Chairman of its Board of Directors starting March 13, 2026, succeeding Tony Hunt, who is retiring. Hunt, who served Repligen for over a decade, will remain an advisor until March 2027. Dr. Madaus brings 36 years of industry experience, including transforming Millipore Corporation into a life sciences leader.
Repligen Elects Dr. Martin D. Madaus as Chair of the Board
Repligen Corporation announced the election of Dr. Martin D. Madaus as the new Chair of its Board, effective March 13, 2026. This follows the retirement of Tony Hunt, who served for over a decade and will transition to an advisory role. Dr. Madaus brings 36 years of industry experience, including leadership roles at Millipore Corporation, and is expected to guide the company's continued growth in bioprocessing technology.
Repligen executive chair Tony Hunt to retire, Martin Madaus to succeed
Repligen Corporation has announced that its executive chair, Tony Hunt, will retire, with Dr. Martin Madaus elected to succeed him as Chair of the Board starting March 13. Hunt will remain an advisor until March 2027. Dr. Madaus joined Repligen's board in February 2023 and brings 36 years of industry experience, including a five-year tenure as Chairman, President, and CEO of Millipore Corporation.
Repligen appoints Madaus as new board chair, Hunt to retire By Investing.com
Repligen Corporation has announced that Dr. Martin D. Madaus will succeed Tony Hunt as the new Chair of the Board, effective March 13, 2026. Hunt, who served Repligen for over a decade, will transition to an advisory role until March 2027. This leadership change follows recent strong financial performance by Repligen, with Q3 2025 earnings surpassing market expectations, leading to updated price targets from Jefferies and Stifel.
Repligen Corporation Elects Dr. Martin D. Madaus as New Chair of the Board, Succeeding Tony Hunt
Repligen Corporation has announced the election of Dr. Martin D. Madaus as the new Chair of its Board of Directors, effective March 13, 2026. He will succeed Tony Hunt, who is retiring from his role as Executive Chair after more than a decade of service but will continue as an advisor until March 2027. Dr. Madaus, who joined the board in February 2023, brings extensive bioprocessing and biopharma experience, having previously led Millipore Corporation.
Repligen appoints Madaus as new board chair, Hunt to retire By Investing.com
Repligen Corporation announced that Dr. Martin D. Madaus will become the new Chair of the Board, succeeding Tony Hunt, who is retiring but will continue as an advisor through March 2027. Dr. Madaus, with extensive industry experience and former leadership at Millipore Corporation, joined Repligen's board in February 2023. This leadership change comes as Repligen, valued at $9.5 billion, and trading near its 52-week high, recently surpassed Q3 2025 earnings expectations, leading to raised price targets from analysts.
Repligen Appoints Martin Madaus as New Board Chair
Repligen has announced the appointment of independent director Dr. Martin D. Madaus as its new Chair of the Board, effective March 13, 2026. He will succeed Executive Chair Tony Hunt, who will retire but remain an advisor through March 2027 to ensure a smooth transition. Madaus's extensive industry experience is expected to guide Repligen through its next phase of growth while maintaining strong governance and strategic continuity.
Repligen Corporation Elects Dr. Martin D. Madaus as New Chair of the Board, Succeeding Tony Hunt
Repligen Corporation has elected Dr. Martin D. Madaus as the new Chair of the Board, effective March 13, 2026, following Tony Hunt's retirement after more than a decade of service. Dr. Madaus, who has extensive experience in bioprocessing and biopharmaceuticals, will lead Repligen as Tony Hunt continues as an advisor through March 2027. This transition aims to build upon Repligen's strong foundation with Dr. Madaus's leadership guiding the company to new phases of growth.
Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair
Repligen Corporation announced that Dr. Martin D. Madaus has been elected as Chair of the Board, effective March 13, 2026, succeeding Tony Hunt who is retiring. Mr. Hunt will continue to serve as an advisor through March 2027. Olivier Loeillot, Repligen President and CEO, expressed gratitude for Hunt's service and confidence in Madaus's leadership, citing his extensive industry experience.
Repligen appoints Madaus as new board chair, Hunt to retire
Repligen Corporation announced that Dr. Martin D. Madaus will succeed Tony Hunt as Chair of the Board, effective March 13, 2026. Hunt will retire from his role but will remain an advisor through March 2027. Dr. Madaus brings extensive industry experience, having previously led Millipore Corporation, and his appointment follows Repligen's strong Q3 2025 earnings and positive analyst outlook.
Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair
Repligen Corporation announced that its Executive Chair, Tony Hunt, will retire from his role and the Board of Directors on March 13, 2026. Dr. Martin D. Madaus has been elected as the new Chair of the Board, effective the same date. Hunt will continue as an advisor through March 2027, and Repligen's CEO Olivier Loeillot expressed confidence in Dr. Madaus's leadership to build on the company's strong foundation.
Longtime Repligen leader steps down as new board chair takes over in 2026
Repligen (NASDAQ: RGEN) announced that Dr. Martin D. Madaus was elected Chair of the Board, effective March 13, 2026, as Executive Chair Tony Hunt retires from the Board on that date. Hunt will remain as an advisor through March 2027. Dr. Madaus, who has 36 years of industry experience and has served as a Repligen director since February 2023, is expected to guide the company's bioprocessing strategy.
